Related Experiment Video
Updated: Jun 15, 2025
09:16
A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors
Published on: October 30, 2016
11.2K
Vaccines against mpox: MVA-BN and LC16m8
John D Grabenstein1, Adam Hacker2
1Vaccine Dynamics, Easton, MD, USA.
Expert Review of Vaccines
|August 27, 2024
Summary
Two mpox vaccines, MVA-BN and LC16m8, are available globally. Real-world data confirm MVA-BN
Area of Science:
- Virology
- Immunology
- Public Health
Background:
- Global mpox outbreaks, including clade IIb and clade I, persist.
- Mpox can cause severe disease and death.
- Vaccination is a key preventive strategy.
Purpose of the Study:
- To review human and animal data on MVA-BN and LC16m8 mpox vaccines.
- To summarize real-world evidence from 2022-2024 mpox outbreaks.
- To assess vaccine safety and efficacy across different mpox clades.
Main Methods:
- Review of pivotal animal studies (e.g., nonhuman primate lethal-challenge models).
- Analysis of human clinical trial data.
- Examination of real-world effectiveness data from recent mpox outbreaks.
Main Results:
- Both MVA-BN and LC16m8 have established safety profiles and regulatory approvals.
- MVA-BN demonstrates clear effectiveness as primary preventive vaccination against clade IIb mpox in real-world studies.
- Effectiveness against clade I mpox is supported by animal studies for both vaccines.
Conclusions:
- MVA-BN and LC16m8 are reliable mpox vaccines with strong safety records.
- MVA-BN's replication incompetence and LC16m8's pediatric data are notable features.
- Further real-world data in diverse populations and settings are needed.
